L
LTZ Therapeutics
Develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need
About LTZ Therapeutics
LTZ Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary Myeloid Engager Platform is designed to activate and enhance the function of myeloid cells, a type of immune cell, to generate a robust and durable anti-tumor response.
Read full description
LTZ's lead product candidate, LTX-001, is a monoclonal antibody that targets a specific receptor on myeloid cells and is currently in Phase 1 clinical trials for the treatment of solid tumors. The company is also developing a pipeline of other myeloid engager candidates for various cancer indications and autoimmune diseases. With operations in both the United States and China, LTZ Therapeutics is strategically positioned to access global talent and resources to advance its innovative pipeline.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Redwood City, United States
- Employees
- 43
- Open positions
- 1
- Dealroom signal
- 86.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2026 | $38M | $400M | GL Ventures | ↗ |
| SERIES AOther financing | Apr 2025 | $40M | $400M | Hillhouse Capital · Zoo Capital · BlueRun Ventures · 5Y Capital | ↗ |
Growth signals
Latest recorded traffic for LTZ Therapeutics is 2.3K monthly website visits, up 109.1% over the last three months. LTZ Therapeutics's team grew 4.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
K2 Global
K2 Venture Capital
Hangzhou Tigermed
Shunwei Capital- K2K2VC
Shenzhen Leaguer Venture Capital
Series A8 investors entered at this stage
Lapam Capital
GL Ventures
K2 Venture Partners
Zoo Capital
Hillhouse Capital
BlueRun Ventures
5Y Capital
Unicorn Capital Partners
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LTZ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LTZ Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.